Advanced search
Publication Cover
Modern Rheumatology Case Reports Volume 5, 2021 - Issue 1
Journal homepage
2,989
Views
24
CrossRef citations to date
0
Altmetric
Case Reports

Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: a case report

Cristian Quintana-Ortegaa Pediatric Rheumatology Department, La Paz Children´s Hospital, Madrid, SpainCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-1680-3599
ORCID Icon,
Agustín Remesala Pediatric Rheumatology Department, La Paz Children´s Hospital, Madrid, Spain
,
Marta Ruiz de Valbuenab Pediatric Pulmonology Department, La Paz Children’s Hospital, Madrid, Spain
,
Olga de la Sernab Pediatric Pulmonology Department, La Paz Children’s Hospital, Madrid, Spain
,
María Laplaza-Gonzálezc Pediatric Intensive Care Unit, La Paz Children’s Hospital, Madrid, Spain
,
Elena Álvarez-Rojasc Pediatric Intensive Care Unit, La Paz Children’s Hospital, Madrid, Spain
,
Clara Udaondoa Pediatric Rheumatology Department, La Paz Children´s Hospital, Madrid, Spain
,
Rosa Alcobendasa Pediatric Rheumatology Department, La Paz Children´s Hospital, Madrid, Spain
&
Sara Muriasa Pediatric Rheumatology Department, La Paz Children´s Hospital, Madrid, Spain
 show all
Pages 101-107 | Received 09 Jun 2020, Accepted 23 Sep 2020, Published online: 20 Oct 2020

References

  • Kurtzman DJB, Vleugels RA. Anti-melanoma differentiation-associated gene 5 (MDA5) dermatomyositis: a concise review with an emphasis on distinctive clinical features. J Am Acad Dermatol. 2018;78(4):776–785.
  • Kobayashi I, Okura Y, Yamada M, et al. Anti-Melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis. J Pediatr. 2011;158(4):675–677.
  • Kobayashi N, Takezaki S, Kobayashi I, et al. Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis. Rheumatology. 2015;54(5):784–791.
  • Le Goff B, Chérin P, Cantagrel A, et al. Pneumomediastinum in interstitial lung disease associated with dermatomyositis and polymyositis. Arthritis Rheum. 2009; 61(1):108–118.
  • Matsushita T, Mizumaki K, Kano M, et al. Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis. Br J Dermatol. 2017;176(2):395–402.
  • Zampieri S, Ghirardello A, Iaccarino L, et al. Polymyositis-dermatomyositis and infections. Autoimmunity. 2006;39(3):191–196.
  • Stanojevic S. Standardisation of lung function test interpretation: Global Lung Function Initiative. Lancet Respir Med. 2018; 6(1):10–12.
  • Fardet L, Galicier L, Lambotte O, et al. Development and validation of the Hscore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66(9):2613–2620.
  • Sato S, Hoshino K, Satoh T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum. 2009;60(7):2193–2200.
  • Tsuji H, Nakashima R, Hosono Y, et al. Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Arthritis Rheumatol. 2020;72(3):488–498.
  • Kobayashi I, Akioka S, Kobayashi N, et al. Clinical practice guidance for juvenile dermatomyositis (JDM) 2018-Update [published correction appears in Mod Rheumatol. 2020 May;30(3):607]. Mod Rheumatol. 2020;30(3):411–423.
  • Tansley SL, Betteridge ZE, Gunawardena H, et al. Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study. Arthritis Res Ther. 2014;16(4):R138–Published 2014 Jul 2.
  • Sabbagh S, Pinal-Fernandez I, Kishi T, et al. Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis. Ann Rheum Dis. 2019;78(7):988–995.
  • Hall JC, Casciola-Rosen L, Samedy LA, et al. Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res. 2013;65(8):1307–1315.
  • Gono T, Sato S, Kawaguchi Y, et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology. 2012;51(9):1563–1570.
  • Sabbagh S, Almeida de Jesus A, Hwang S, et al. Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib. Brain. 2019;142(11):e59.
  • Poddighe D, Dauyey K. Macrophage activation syndrome in juvenile dermatomyositis: a systematic review. Rheumatol Int. 2020;40(5):695–702.
  • Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620–2629.
  • Henry BM, de Oliveira MHS, Benoit S, et al. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med. 2020; 58(7):1021–1028.
  • Li Y, Hu Y, Yu J, et al. Retrospective analysis of laboratory testing in 54 patients with severe- or critical-type 2019 novel coronavirus pneumonia. Lab Invest. 2020;100(6):794–800.
  • Kobayashi I, Kawamura N, Okano M, et al. Thrombocytopaenia in juvenile dermatomyositis. Scand J Rheumatol. 2006;35(1):79–80.
  • Yajima N, Wakabayashi K, Odai T, et al. Clinical features of hemophagocytic syndrome in patients with dermatomyositis. J Rheumatol. 2008; 35(9):1838–1841.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.